SCHEMBL582990

SCHEMBL582990

CNC(=O)CNC(=O)CN

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 1/20 0.40
ALDH1A1 P00352 1/20 0.36
LMNA P02545 2/20 0.36
MCL1 Q07820 1/20 0.36
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
RECQL P46063 1/20 0.32
MMP2 P08253 1/20 0.32
PRMT3 O60678 1/20 0.31
FUCA1 P04066 1/20 0.31
AOC3 Q16853 2/20 0.31
GLRA1 P23415 1/20 0.30
SLC6A9 P48067 1/20 0.30
OR51E2 Q9H255 1/20 0.30
KDM4E B2RXH2 1/20 0.30
KDM5C P41229 1/20 0.30
EGLN1 Q9GZT9 1/20 0.30
PHF8 Q9UPP1 1/20 0.30
KDM2A Q9Y2K7 1/20 0.30
MALT1 Q9UDY8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9971593 0.98 TERT (0.39) TERTALDH1A1LMNAMCL1CA1
SCHEMBL210050 0.81
Hydrochloric Acid SCHEMBL9317289 0.78
Hydrochloric Acid SCHEMBL719172 0.78
SCHEMBL24261804 0.78 TERT (0.39) TERTLMNACA1CA2RECQL
SCHEMBL17980508 0.78 TERT (0.39) TERTLMNACA1CA2RECQL
SCHEMBL13660545 0.78 MCL1 (0.41) TERTALDH1A1LMNAMCL1CA1
SCHEMBL17874650 0.78 MCL1 (0.41) TERTALDH1A1LMNAMCL1CA1
SCHEMBL19985684 0.78 MCL1 (0.41) TERTALDH1A1LMNAMCL1CA1
SCHEMBL15700609 0.78 TERT (0.39) TERTLMNACA1CA2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106636013-A Ankara virus strain FAdV-HB and preparation and application of inactivated vaccine of ankara virus strain FAdV-HB 华中农业大学 2017-05-10 CN claimed
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 US disclosed
WO-2023178641-A1 DNA TOXIC DIMER COMPOUND AND CONJUGATE THEREOF 成都百利多特生物药业有限责任公司 2023-09-28 WO disclosed
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-08 US disclosed
EP-3812376-A1 PACLITAXEL-LIPID-POLYSACCHARIDE DUAL-TYPE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF Santolecan Pharmaceuticals LLC (US) 2021-04-28 EP disclosed
US-20200376013-A1 SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE AVELAS BIOSCIENCES, INC. 2020-12-03 US disclosed
WO-2020234167-A1 PRINTABLE HYDROGEL, METHOD FOR GENERATING A PRINTABLE HYDROGEL, LYOPHILIZATE, PRINTED PRODUCT AND 3D PRINTING METHOD ETH Zürich (CH) 2020-11-26 WO disclosed
US-20190076547-A1 ANTIBODY ADJUVANT CONJUGATES BOLT BIOTHERAPEUTICS, INC. 2019-03-14 US disclosed
EP-2350120-B1 MULTILIGAND CONSTRUCTS SEMIOTIK LLC (RU) 2017-10-11 EP disclosed
CN-106636013-A Ankara virus strain FAdV-HB and preparation and application of inactivated vaccine of ankara virus strain FAdV-HB 华中农业大学 2017-05-10 CN disclosed
US-20140024640-A1 Benzazepine Derivatives Useful as Vasopressin Antagonists OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-23 US disclosed
US-20140024619-A1 Benzazepine Derivatives Useful as Vasopressin Antagonists OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-23 US disclosed
EP-2374798-B1 Benzazepine derivatives useful as vasopressin antagonists OTSUKA PHARMA CO LTD (JP) 2013-09-04 EP disclosed
EP-2170831-B1 Benzazepine derivatives useful as vasopressin antagonists OTSUKA PHARMA CO LTD (JP) 2012-02-15 EP disclosed
EP-2374797-A1 Benzazepine derivatives useful as vasopressin antagonists OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-10-12 EP disclosed
EP-2374798-A1 Benzazepine derivatives useful as vasopressin antagonists OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-10-12 EP disclosed
US-20110071084-A1 BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-03-24 US disclosed
EP-2170831-A1 BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS Otsuka Pharmaceutical Co., Ltd. (JP) 2010-04-07 EP disclosed
US-20100036111-A1 METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS RIKEN (JP) 2010-02-11 US disclosed
WO-2009001968-A1 BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP TERT 4841/4885ALDH1A1 3596/4885LMNA 1538/4885
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS VIP, DNPEP, PEPD TERT 4603/4885ALDH1A1 4110/4885LMNA 3184/4885
US-20100036111-A1 METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS POLM, POLL, POLRMT TERT 579/4885ALDH1A1 2586/4885LMNA 3624/4885
US-20200376013-A1 SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE ABCG2, CD44, PITRM1 TERT 4860/4885ALDH1A1 3790/4885LMNA 443/4885
US-20190076547-A1 ANTIBODY ADJUVANT CONJUGATES FCGR1A, FCGR3B, FCGR2A TERT 1356/4885ALDH1A1 954/4885LMNA 4851/4885
US-20110071084-A1 BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS AVPR2, AVPR1B, AVPR1A TERT 3784/4885ALDH1A1 1456/4885LMNA 2356/4885
US-20140024619-A1 Benzazepine Derivatives Useful as Vasopressin Antagonists AVPR2, AVPR1B, AVPR1A TERT 3790/4885ALDH1A1 1410/4885LMNA 2291/4885
US-20140024640-A1 Benzazepine Derivatives Useful as Vasopressin Antagonists AVPR2, AVPR1B, AVPR1A TERT 3790/4885ALDH1A1 1410/4885LMNA 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.